NDAORALTABLET
Approved
May 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
3/8 — Basic
GLUCOTROL (glipizide) by Pfizer is pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. First approved in 1984.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLUCOTROL (glipizide) is an oral sulfonylurea small-molecule insulin secretagogue approved in 1984 for Type 2 Diabetes Mellitus and hyperglycemia. It works by binding to sulfonylurea receptors on pancreatic beta cells, closing ATP-sensitive potassium channels and stimulating insulin release. The drug is indicated for Type 2 Diabetes, Hyperglycemia, Chronic Kidney Disease, and Atherosclerosis.
LOE Approaching
As lifecycle maturity approaches LOE, the brand team is focused on defending market position against newer mechanisms; team size and investment likely stable or declining.
Mechanism of Action
pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (11)
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
Started Sep 2014
100 enrolled
Diabetes Mellitus Type 2Hyperglycemia
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Started Mar 2009
2,639 enrolled
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
Started Jun 2008
441 enrolled
Diabetes Mellitus
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
Started Oct 2007
129 enrolled
Diabetes Mellitus, Type 2End-Stage Kidney Disease
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
Started Oct 2007
426 enrolled
Diabetes Mellitus, Type 2Renal Insufficiency, Chronic
Worked on GLUCOTROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.